Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | ACACB | O00763 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001114 | 0.87 | ACACB (0.46) | HSD11B1ACACBALDH1A1LMNAMAPT | |
| SCHEMBL19001042 | 0.87 | ACACB (0.46) | HSD11B1ACACBALDH1A1LMNAMAPT | |
| SCHEMBL19001084 | 0.87 | ACACB (0.46) | HSD11B1ACACBALDH1A1LMNAMAPT | |
| SCHEMBL18436754 | 0.87 | GPR119 (0.56) | HSD11B1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL24681357 | 0.86 | GPR119 (0.43) | HSD11B1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL5726247 | 0.86 | GPR119 (0.43) | HSD11B1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL6073574 | 0.86 | GPR119 (0.43) | HSD11B1GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL21336726 | 0.86 | GPR119 (0.56) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL7661674 | 0.85 | GPR119 (0.58) | GPR119ALDH1A1LMNAMAPTHTT | |
| SCHEMBL7661671 | 0.85 | GPR119 (0.58) | GPR119ALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | HSD11B1 3620/4885GPR119 1965/4885ACACB 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.